rct1100
Nucleic acidexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2023 (NCT05737485)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transmembrane protease serine 2ANTISENSE INHIBITOR
TMPRSS2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06633757 | Phase 1 | Nov 1, 2024 | ReCode Therapeutics, University of Copenhagen, University of Munster |
| NCT06600425 | Phase 1 | Sep 20, 2024 | ReCode Therapeutics |
| NCT05737485 | Phase 1 | Feb 18, 2023 | ReCode Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ReCode Therapeutics | For profit | 3 | 3 | 1 | 2023 |
| University of Copenhagen | Academic/Hospital | 1 | 0 | 1 | 2024 |
| University of Munster | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1